
Quarterly report 2022-Q2
added 12-23-2023
Zymeworks EPS Ratio 2011-2025 | ZYME
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Zymeworks
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.11 | -3.58 | -3.83 | -1.26 | -0.51 | -2.65 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.51 | -4.11 | -2.66 |
Quarterly EPS Ratio Zymeworks
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -0.97 | -1.18 | - | -1.17 | -1.31 | -0.87 | -0.74 | -1.43 | -0.77 | -0.64 | -1.66 | -0.7 | -0.89 | -0.43 | - | -0.59 | -0.22 | -0.83 | - | -0.64 | -0.55 | -1.21 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.22 | -1.66 | -0.884 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.87 | 11.68 % | $ 477 M | ||
|
Aclaris Therapeutics
ACRS
|
-1.71 | $ 3.0 | -0.99 % | $ 232 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.1 | -0.64 % | $ 7.46 B | ||
|
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
-0.78 | $ 1.1 | -3.51 % | $ 6 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 211.15 | 1.04 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
BioVie
BIVI
|
-12.1 | $ 1.22 | 0.83 % | $ 1.8 M | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 0.17 | -18.84 % | $ 370 M | ||
|
Berkeley Lights
BLI
|
-1.42 | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 95.17 | 0.69 % | $ 27.2 B | ||
|
Catalyst Biosciences
CBIO
|
-1.41 | $ 12.12 | -1.86 % | $ 798 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
3.29 | $ 26.86 | -0.96 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B | ||
|
Anika Therapeutics
ANIK
|
-5.64 | $ 9.53 | -0.21 % | $ 140 M | ||
|
Certara
CERT
|
-0.08 | $ 8.85 | -0.45 % | $ 1.42 B | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
-2.55 | $ 4.95 | 4.2 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
4.98 | $ 583.1 | -0.13 % | $ 44.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.55 | 4.08 % | $ 16 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | $ 92.68 | -0.24 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
0.11 | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 9.25 | 1.82 % | $ 1.49 B | ||
|
Celldex Therapeutics
CLDX
|
-2.45 | $ 25.93 | -1.8 % | $ 1.67 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-13.1 | $ 11.43 | 2.65 % | $ 739 M |